title: Reversible disassembly of transcription domains in lymphocyte nuclei during inhibition of RNA synthesis by DRB.
abstract: We are investigating the roles of RNA synthesis, chromatin structure and nuclear matrix organization in establishing and maintaining transcription domains, using mitogen stimulated lymphocytes as a model system. In a continuing study, the effects of the RNA polymerase inhibitor DRB and of its removal on nuclear organization have been examined by EM cytochemistry and by immunofluorescence labelling of the nuclear matrix PI1, Sm and nucleolar fibrillarin antigens. Chromatin, interchromatin granules and nucleoli were extensively restructured after DRB, as were matrix antigens. According to cytochemical staining properties, the conformation of DRB-induced condensed chromatin resembled that in partially stimulated lymphocytes. The nucleoplasmic fibrogranular RNP network appeared little altered, but the fibrillar proteinaceous interchromatinic regions, interpreted as representing the nuclear matrix in situ, were more affected. After removal of DRB, nuclei recovered the organization and transcriptional activity of controls within 8 h. These results suggest that the matrix subtending transcription domains remains stable when transcription is arrested, even though the chromatin and individual RNP components of the domains are disorganized. The data further indicate that absence of transcription is not solely accountable for the highly aggregated state of the chromatin in resting lymphocytes.
authors.affiliation: Department of Biology, Carleton University, Ottawa, Ontario, Canada.
authors.forename: L
authors.initials: L
authors.lastname: Davis
authors.forename: M
authors.initials: M
authors.lastname: Cadrin
authors.forename: D L
authors.initials: DL
authors.lastname: Brown
authors.forename: N
authors.initials: N
authors.lastname: Chaly
mesh_terms: D000818:Animals; D001324:Autoantigens / Q000032:analysis; D002467:Cell Nucleus / Q000187:drug effects / Q000648:ultrastructure*; D002843:Chromatin / Q000378:metabolism / Q000648:ultrastructure; D002868:Chromosomal Proteins, Non-Histone / Q000032:analysis; D003208:Concanavalin A / Q000494:pharmacology; D004004:Dichlororibofuranosylbenzimidazole / Q000494:pharmacology*; D005455:Fluorescent Antibody Technique; D007700:Kinetics; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008854:Microscopy, Electron; D015530:Nuclear Matrix / Q000378:metabolism / Q000648:ultrastructure; D012313:RNA / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D012342:RNA, Small Nuclear / Q000032:analysis; D012261:Ribonucleoproteins / Q000032:analysis; D017411:Ribonucleoproteins, Small Nuclear; D013154:Spleen / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*; D014529:Uridine / Q000378:metabolism; D055517:snRNP Core Proteins
chemical_list: D001324:Autoantigens; D002843:Chromatin; D002868:Chromosomal Proteins, Non-Histone; D012342:RNA, Small Nuclear; D012261:Ribonucleoproteins; D017411:Ribonucleoproteins, Small Nuclear; C047458:fibrillarin; D055517:snRNP Core Proteins; D003208:Concanavalin A; D004004:Dichlororibofuranosylbenzimidazole; D012313:RNA; D014529:Uridine